| scholarly article | Q13442814 |
| P50 | author | Patrick W Serruys | Q63253317 |
| P2093 | author name string | Bernhard Meier | |
| Angelo Branzi | |||
| Carlos Macaya | |||
| Graham Jackson | |||
| Marcelo C Bertolami | |||
| Bradley Strauss | |||
| Pim de Feyter | |||
| Jacques Puel | |||
| Lescol Intervention Prevention Study (LIPS) Investigators | |||
| Matthias Vrolix | |||
| Norbert Kokott | |||
| P433 | issue | 24 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3215-3222 | |
| P577 | publication date | 2002-06-01 | |
| P1433 | published in | The Journal of the American Medical Association | Q1470970 |
| P1476 | title | Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial | |
| P478 | volume | 287 |
| Q28301815 | 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines |
| Q49396285 | 2016 Chinese guidelines for the management of dyslipidemia in adults |
| Q63694272 | 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol |
| Q64080237 | 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension |
| Q38992196 | A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies. |
| Q37680946 | A clinical review of statins and cancer: helpful or harmful? |
| Q43013574 | A comparison of coronary artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery: five year clinical follow up. |
| Q45107476 | A prudent algorithm for hyperlipoproteinemia in renal transplant recipients |
| Q28218403 | A randomized trial to assess the impact of opinion leader endorsed evidence summaries on the use of secondary prevention strategies in patients with coronary artery disease: the ESP-CAD trial protocol [NCT00175240] |
| Q44646770 | A retrospective analysis of the effect of noncompliance on time to first major adverse cardiac event in LIPS. |
| Q26747195 | A review of low-density lipoprotein cholesterol, treatment strategies, and its impact on cardiovascular disease morbidity and mortality |
| Q38546910 | A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention |
| Q34154695 | ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice g |
| Q37398039 | Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study |
| Q36320553 | Acute coronary syndromes and diabetes mellitus |
| Q33972105 | Adherence with statins in a real-life setting is better when associated cardiovascular risk factors increase: a cohort study |
| Q31101617 | All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. |
| Q44951488 | An economic evaluation of fluvastatin used for the prevention of cardiac events following successful first percutaneous coronary intervention in the UK. |
| Q28251955 | Angiotensin antagonism in coronary artery disease: results after coronary revascularisation |
| Q28166001 | Application of Current Guidelines to the Management of Unstable Angina and Non-ST-Elevation Myocardial Infarction |
| Q41570709 | Aspergillus awamori feeding modifies lipid metabolism in rats |
| Q53280853 | Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. |
| Q46621249 | Atherosclerosis imaging and circulating blood biomarkers: insights into subclinical atherosclerotic plaque burden and disease activity |
| Q42859163 | Attainment of Canadian and European guidelines’ lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin |
| Q37886975 | Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs: impact on clinical outcomes. |
| Q35809770 | Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies |
| Q35582952 | Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS). |
| Q35560581 | Beneficial effects of statins after percutaneous coronary intervention |
| Q36835515 | Benefit/risk ratio of statins in primary prevention |
| Q28196396 | Benefits of optimising drug treatment in home-dwelling elderly patients with coronary artery disease |
| Q35734332 | Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins |
| Q73739828 | C-reactive protein and coronary events following percutaneous coronary angioplasty |
| Q37413636 | Can statins reduce risk of lung cancer, especially among elderly people? A meta-analysis |
| Q28821882 | Cancer risk in older people receiving statin therapy: a meta-analysis of randomized controlled trials |
| Q78638408 | Cardioprotective effects of an early invasive strategy for non-ST-segment elevation acute coronary syndromes: are we all becoming "interventional" cardiologists? |
| Q36093161 | Cardiovascular prevention in type 2 diabetic patients: review of efficacious treatments. |
| Q35706632 | Catheter-based treatment of atherosclerosis. Options for effective percutaneous intervention are plentiful |
| Q45002820 | Characteristics of US adults with the metabolic syndrome and therapeutic implications |
| Q36536175 | Cholesterol lowering for secondary prevention: what statin dose should we use? |
| Q36812806 | Clinical efficacy and safety of statins in managing cardiovascular risk |
| Q35722920 | Clinical trials and lipid guidelines for type II diabetes |
| Q35194386 | Combination lipid-lowering therapy with statins: safety issues in the postcerivastatin era. |
| Q36131805 | Comprehensive imaging of coronary artery disease: impact on contemporary treatment approaches |
| Q40441608 | Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention |
| Q38099287 | Defining the role of high-dose statins in PCI. |
| Q35107076 | Diabetes: can we stop the time bomb? |
| Q33446544 | Diabetes: managing dyslipidaemia |
| Q35774830 | Diabetes: preventing coronary heart disease in a high risk group |
| Q37634190 | Does simvastatin cause more myotoxicity compared with other statins? |
| Q36577189 | Drug insight: Immunomodulatory effects of statins--potential benefits for renal patients? |
| Q33376862 | Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). |
| Q52564491 | Effect of Stains on LDL Reduction and Liver Safety: A Systematic Review and Meta-Analysis. |
| Q37435145 | Effect of atorvastatin-eluting stents in a rabbit iliac artery restenosis model |
| Q40338516 | Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency |
| Q44483019 | Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial |
| Q34571157 | Effect of lower targets for blood pressure and LDL cholesterol on atherosclerosis in diabetes: the SANDS randomized trial |
| Q50082633 | Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials |
| Q37981596 | Effect of statins on ventricular tachyarrhythmia, cardiac arrest, and sudden cardiac death: a meta-analysis of published and unpublished evidence from randomized trials |
| Q39031198 | Effect of statins type on incident prostate cancer risk: a meta-analysis and systematic review. |
| Q52666977 | Effectiveness of revascularization interventions compared with medical therapy in patients with ischemic cardiomyopathy: A systematic review protocol. |
| Q33938868 | Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect |
| Q39851153 | Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease |
| Q44530603 | Effects of statins on C-reactive protein and interleukin-6 (the Ludwigshafen Risk and Cardiovascular Health study). |
| Q51051675 | Effects of statins on restenosis after coronary stent implantation. |
| Q29547856 | Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins |
| Q29617910 | Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials |
| Q36912033 | Efficacy and safety of statin monotherapy in older adults: a meta-analysis |
| Q34142678 | Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials |
| Q46810855 | Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis |
| Q34601330 | Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials |
| Q34456192 | Efficacy of standard and intensive statin treatment for the secondary prevention of cardiovascular and cerebrovascular events in diabetes patients: a meta-analysis |
| Q37588002 | Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era. |
| Q25255887 | Evidence-based prescribing of statins: a developing world perspective |
| Q40819733 | Expression of OATP2B1 as determinant of drug effects in the microcompartment of the coronary artery. |
| Q33945130 | Facts and principles learned at the 32nd annual Williamsburg Conference on Heart Disease |
| Q35879055 | Fluvastatin and fluvastatin extended release: a clinical and safety profile. |
| Q56386465 | Fluvastatin for lowering lipids |
| Q35807245 | Fluvastatin: clinical and safety profile |
| Q36249930 | Fluvastatin: efficacy and safety in reducing cardiac events |
| Q37451199 | From 4S to IDEAL: the health economics of the statin trials |
| Q28195662 | Guidelines for Improving the Care of the Older Person with Diabetes Mellitus |
| Q38720697 | Guidelines for Management of Hyperlipidemia: Implications for Treatment of Patients with Stroke Secondary to Atherosclerotic Disease. |
| Q24187314 | HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass |
| Q37466728 | High-dose atorvastatin pretreatment could diminishes microvascular impairment in patients undergoing elective percutaneous coronary intervention |
| Q44233372 | High-risk elderly patients PROSPER from cholesterol-lowering therapy |
| Q41542147 | Human electronegative low-density lipoprotein modulates cardiac repolarization via LOX-1-mediated alteration of sarcolemmal ion channels. |
| Q36262786 | Identification of new biosignatures for clinical outcomes in stable coronary artery disease - The study protocol and initial observations of a prospective follow-up study in Taiwan |
| Q57136141 | Impact of Omega-3 Supplementation on High Sensitive C-Reactive Protein Level and 30-Day Major Adverse Cardiac Events After the Implementation of Coronary Stent in Patients with Chronic Kidney Disease: A Randomized Clinical Study |
| Q31118791 | Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. |
| Q47224815 | Implementation of smart technology to improve medication adherence in patients with cardiovascular disease: is it effective? |
| Q37016141 | Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention |
| Q37189927 | Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance |
| Q37792117 | Inflammatory markers, cholesterol and statins: pathophysiological role and clinical importance. |
| Q37728858 | Influence of fluvastatin on cardiac function and baroreflex sensitivity in diabetic rats |
| Q36243281 | Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis |
| Q92158280 | Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants |
| Q37312136 | Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertensi |
| Q35206383 | Ischemic heart disease in type 2 diabetes |
| Q93646096 | JournalScan |
| Q24630160 | Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean? |
| Q35988999 | LDL-lowering therapy and the risk of prostate cancer: a meta-analysis of 6 randomized controlled trials and 36 observational studies. |
| Q35009456 | Lack of therapeutic interchangeability of HMG-CoA reductase inhibitors |
| Q57024998 | Legacy effects of statins on cardiovascular and all-cause mortality: a meta-analysis |
| Q46951294 | Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. |
| Q37853015 | Lipid control in patients with diabetes mellitus |
| Q36331015 | Lipids and stroke: the opportunity of lipid-lowering treatment |
| Q84614031 | Long-term changes in neointimal hyperplasia following implantation of bare metal stents assessed by integrated backscatter intravascular ultrasound |
| Q82413587 | Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (≥65 years old) |
| Q34207135 | Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors |
| Q79233378 | Low-density lipoprotein cholesterol lowering in the prevention of CHD: how low should we go? |
| Q35856876 | Low-density lipoprotein reduction in high-risk patients: how low do you go? |
| Q36645630 | Lower is better--the contemporary concept of low-density lipoprotein lowering in the preventive management of cardiovascular risk: does this apply to all patients? |
| Q89040695 | Lowering LDL-Cholesterol and CV Benefits: Is There a Limit to How Low LDL-C Needs to be for Optimal Health Benefits? |
| Q36369808 | Management of dyslipidemia in elderly diabetic patients. |
| Q44416959 | Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol |
| Q35077211 | Mechanisms of plaque stabilization with statins |
| Q35610914 | Medical angioplasty - hope and expectations: an optimistic overview |
| Q35782818 | Medical lipid-regulating therapy: current evidence, ongoing trials and future developments |
| Q38083007 | Medical management of stable coronary atherosclerosis. |
| Q35826088 | Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes |
| Q33729671 | Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins |
| Q37119203 | Missed opportunities for the secondary prevention of cardiovascular disease in Canada |
| Q37336662 | Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study |
| Q60305797 | Moderate-intensity versus high-intensity statin therapy in Korean patients with angina undergoing percutaneous coronary intervention with drug-eluting stents: A propensity-score matching analysis |
| Q45036700 | Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). |
| Q37322277 | Mortality differences between men and women after percutaneous coronary interventions. A 25-year, single-center experience |
| Q36072457 | Myopathy in older people receiving statin therapy: a systematic review and meta-analysis |
| Q33195764 | New and emerging data from clinical trials of statins |
| Q35035100 | Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia |
| Q54055601 | Non-cardiovascular mortality, low-density lipoprotein cholesterol and statins: a meta-regression analysis. |
| Q35077225 | Optimizing lipid management in patients with acute coronary syndromes |
| Q36475343 | Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly |
| Q85830493 | Patients' adherence to secondary prevention pharmacotherapy after acute coronary syndromes |
| Q35575681 | Percutaneous coronary intervention: historical perspectives, current status, and future directions |
| Q35587196 | Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies |
| Q37638256 | Pharmacological prevention of peri-, and post-procedural myocardial injury in percutaneous coronary intervention |
| Q28218179 | Pharmacological strategies to reduce cardiovascular risk in type 2 diabetes mellitus: an update |
| Q35610108 | Pitavastatin calcium improves endothelial function and delays the progress of atherosclerosis in patients with hypercholesterolemia |
| Q39069187 | Pleiotropic Effects of Statins on the Cardiovascular System |
| Q64109295 | Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials |
| Q29617817 | Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial |
| Q80209835 | Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study |
| Q37709401 | Predictive value of C-reactive protein after drug-eluting stent implantation |
| Q57281927 | Prevention of Coronary and Stroke Events with Atorvastatin in Hypertensive Patients who have Average or Lower-than-Average Cholesterol Concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial— Lipid Lowering Arm (ASCOT-LLA) |
| Q34189543 | Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra |
| Q55436920 | Projected Real-World Effectiveness of Using Aggressive Low-Density Lipoprotein Cholesterol Targets Among Elderly Statin Users Following Acute Coronary Syndromes in Canada. |
| Q37237515 | Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative |
| Q33776201 | Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis |
| Q36383706 | Reducing the risks of sudden death and heart failure post myocardial infarction: utility of optimized pharmacotherapy |
| Q35383553 | Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. |
| Q35648346 | Relationship between the use of statins and patient survival in colorectal cancer: a systematic review and meta-analysis |
| Q73739845 | Restenosis after coronary intervention: narrowing C-reactive protein's prognostic potential? |
| Q38613429 | Role of Ezetimibe in Lipid-Lowering and Cardiovascular Disease Prevention |
| Q36812986 | Secondary prevention after PCI: the cost-effectiveness of statin therapy in the Netherlands |
| Q41633477 | Secondary prevention of major cerebrovascular events with seven different statins: a multi-treatment meta-analysis |
| Q44324185 | Severe hepatic injury associated with different statins in patients with chronic liver disease: a nationwide population-based cohort study |
| Q35955693 | Should standard medical therapy for angina include a statin? |
| Q34041102 | Sigmoidal maximal effect modeling of low-density lipoprotein cholesterol concentration and annual incidence of coronary heart disease events in secondary prevention trials |
| Q73632581 | Silent ischemia: unsafe at any time |
| Q33946592 | Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network |
| Q36185746 | Statin Intensity and Clinical Outcome in Patients with Stable Coronary Artery Disease and Very Low LDL-Cholesterol |
| Q37786520 | Statin myopathy: a review of recent progress |
| Q44954077 | Statin therapy in patients with atypical chest pain and mild-to-moderate coronary stenosis on 64-slice multidetector coronary computed tomography; a retrospective propensity score matching analysis |
| Q35035835 | Statin use and risk of lung cancer: a meta-analysis of observational studies and randomized controlled trials |
| Q34273115 | Statin use and risk of pancreatic cancer: a meta-analysis. |
| Q35365005 | Statin use and risk of pancreatic cancer: results from a large, clinic-based case-control study |
| Q44560037 | Statin use and the risk of prostate cancer: A metaanalysis of 6 randomized clinical trials and 13 observational studies |
| Q38092053 | Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies. |
| Q89824962 | Statin-mediated cholesterol depletion exerts coordinated effects on the alterations in rat vascular smooth muscle cell biomechanics and migration |
| Q35783702 | Statins and liver toxicity: a meta-analysis |
| Q34086279 | Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials |
| Q34585294 | Statins and risk of cancer: a systematic review and metaanalysis |
| Q29622947 | Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials |
| Q21559688 | Statins and the risk of lung cancer: a meta-analysis |
| Q33500185 | Statins and total (not LDL) cholesterol concentration and outcome of myocardial infarction: results from a meta-analysis and an observational study |
| Q36088110 | Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. |
| Q36768488 | Statins as first-line therapy for acute coronary syndrome? |
| Q36153656 | Statins can delay insulin use and reduce diabetes-related diseases in Asian patients with type 2 diabetes |
| Q24193862 | Statins for acute coronary syndrome |
| Q24236697 | Statins for acute coronary syndrome |
| Q24243557 | Statins for acute coronary syndrome |
| Q75354698 | Statins for primary prevention: strategic options to save lives and money |
| Q38025837 | Statins in acute coronary syndrome: very early initiation and benefits |
| Q37276466 | Statins in the first-line therapy of acute coronary syndrome - similar to aspirin? |
| Q28200294 | Statins in the treatment of chronic heart failure: a systematic review |
| Q45210049 | Statins utilisation pattern: a retrospective evaluation in a tertiary care hospital in Thailand. |
| Q26851528 | Statins: definitive translational research |
| Q36428724 | Statins: panacea for sepsis? |
| Q35936339 | Statins: past and present |
| Q37786646 | Stents and statins: history, clinical outcomes and mechanisms |
| Q35839494 | Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction |
| Q34531972 | Systematic review and meta-analysis on the association between outpatient statins use and infectious disease-related mortality |
| Q34541968 | Temporal trends in patient-reported angina at 1 year after percutaneous coronary revascularization in the stent era: a report from the National Heart, Lung, and Blood Institute-sponsored 1997-2006 dynamic registry. |
| Q88739095 | The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations |
| Q34976557 | The association between statin use and the diagnosis of prostate cancer in a population based cohort |
| Q92684654 | The association between statins and colorectal cancer stage in the Women's Health Initiative |
| Q36405134 | The cell cycle: a critical therapeutic target to prevent vascular proliferative disease |
| Q35137013 | The complex interplay between cholesterol and prostate malignancy |
| Q33671245 | The effect of dyslipidemic drugs on mortality: A meta-analysis |
| Q30914775 | The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials |
| Q37072692 | The effect of statins on prostate cancer recurrence and mortality after definitive therapy: a systematic review and meta-analysis |
| Q34274829 | The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials |
| Q34175429 | The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease |
| Q35153749 | The lipid and non-lipid effects of statins |
| Q42501351 | The modification of the muscle fatty acid profile by dietary supplementation with Aspergillus awamori in broiler chickens. |
| Q36176396 | The nurse practitioner's role in helping patients achieve lipid goals with statin therapy |
| Q34636135 | The safety of statins in clinical practice |
| Q57750538 | The use of fluvastatin in cardiovascular risk management |
| Q28196775 | The use of lipid-lowering therapy for secondary prevention in patients undergoing percutaneous coronary intervention |
| Q46755092 | Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. |
| Q35022884 | Thermography of the cardiovascular system |
| Q39807899 | Three-vessel coronary disease in diabetics: personalized versus evidence-based revascularization strategy |
| Q36265996 | Torcetrapib/atorvastatin combination therapy |
| Q45137281 | Towards the optimal management in 2004 of patients with stable coronary artery disease |
| Q35197131 | Toxicity of antilipidemic agents: facts and fictions |
| Q48020713 | Treat-to-target lipid control is effective but highlighted poor prognosis without indication of statin following percutaneous coronary intervention |
| Q35862855 | Treating multivessel disease in the era of coated stents: conclusion. |
| Q35918843 | Treatment of lipids and type 2 diabetes |
| Q37470209 | Update on statin-mediated anti-inflammatory activities in atherosclerosis |
| Q47986997 | Use of Statins for Secondary Prevention |
| Q38030599 | Use of evidence-based therapy for the secondary prevention of acute coronary syndromes in Malaysian practice |
| Q43266396 | Use of fluvastatin following percutaneous coronary intervention |
| Q37897661 | Use of principal component analysis in the evaluation of adherence to statin treatment: a method to determine a potential target population for public health intervention. |
| Q37980478 | Very early initiation of statin therapy and mortality in patients with acute coronary syndrome |
| Q73705083 | [Statin therapy] |
| Q44899028 | fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study |
Search more.